The U.S. Food and Drug Administration (FDA) has designated the Oncuria noninvasive bladder cancer test from Nonagen Bioscience as a breakthrough device.
The company said Oncuria is capable of predicting how a patient will respond to therapy. The multiplex immunoassay measures 10 protein biomarkers in a single voided urine sample.